News
More information: Raajit K. Rampal et al, Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial, Nature Medicine (2025). DOI: 10.1038/s41591-025-03572-3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results